In addition, TAIII treatment increased BAX levels and reduced BCL-2 levels by suppressing the PI3K/Akt/mTOR signaling pathway, showing a new approach for T-ALL therapy. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.